EGFR and lung adenocarcinoma: Similarly, heterogeneity parameters have been shown to predict epidermal growth factor receptor (EGFR) mutation status and treatment response in lung adenocarcinoma patients undergoing EGFR tyrosine kinase inhibitor therapy [16, 17].